These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 23917393)

  • 1. Gefitinib enhances the effects of combined radiotherapy and 5-fluorouracil in a colorectal cancer cell line.
    Palumbo I; Piattoni S; Valentini V; Marini V; Contavalli P; Calzuola M; Vecchio FM; Cecchini D; Falzetti F; Aristei C
    Int J Colorectal Dis; 2014 Jan; 29(1):31-41. PubMed ID: 23917393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II Trial (1839IL/0092).
    Valentini V; De Paoli A; Gambacorta MA; Mantini G; Ratto C; Vecchio FM; Barbaro B; Innocente R; Rossi C; Boz G; Barba MC; Frattegiani A; Lupattelli M; Doglietto GB
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):644-9. PubMed ID: 18395356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer.
    Ogino S; Meyerhardt JA; Cantor M; Brahmandam M; Clark JW; Namgyal C; Kawasaki T; Kinsella K; Michelini AL; Enzinger PC; Kulke MH; Ryan DP; Loda M; Fuchs CS
    Clin Cancer Res; 2005 Sep; 11(18):6650-6. PubMed ID: 16166444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.
    Meyerhardt JA; Clark JW; Supko JG; Eder JP; Ogino S; Stewart CF; D'Amato F; Dancey J; Enzinger PC; Zhu AX; Ryan DP; Earle CC; Mayer RJ; Michelini A; Kinsella K; Fuchs CS
    Cancer Chemother Pharmacol; 2007 Oct; 60(5):661-70. PubMed ID: 17216531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.
    Van Schaeybroeck S; Karaiskou-McCaul A; Kelly D; Longley D; Galligan L; Van Cutsem E; Johnston P
    Clin Cancer Res; 2005 Oct; 11(20):7480-9. PubMed ID: 16243822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective comparison of concurrent bolus 5-fluorouracil or raltitrexed in preoperative chemoradiation for locally advanced rectal cancer.
    Yoney A; Askaroglu B; Hancilar T; Isikli L; Unsal M
    Hematol Oncol Stem Cell Ther; 2008; 1(1):28-33. PubMed ID: 20063525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer.
    Fisher GA; Kuo T; Ramsey M; Schwartz E; Rouse RV; Cho CD; Halsey J; Sikic BI
    Clin Cancer Res; 2008 Nov; 14(21):7074-9. PubMed ID: 18981005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
    Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
    Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of pemetrexed, gefitinib, and their combination on human colorectal cancer cells.
    Zhang G; Xie X; Liu T; Yang J; Jiao S
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):767-75. PubMed ID: 23959460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The optimal schedule for 5-fluorouracil radiosensitization in colon cancer cell lines.
    Ojima E; Inoue Y; Watanabe H; Hiro J; Toiyama Y; Miki C; Kusunoki M
    Oncol Rep; 2006 Nov; 16(5):1085-91. PubMed ID: 17016597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.
    Ready N; Jänne PA; Bogart J; Dipetrillo T; Garst J; Graziano S; Gu L; Wang X; Green MR; Vokes EE;
    J Thorac Oncol; 2010 Sep; 5(9):1382-90. PubMed ID: 20686428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response.
    Javle M; Pande A; Iyer R; Yang G; LeVea C; Wilding G; Black J; Nava H; Nwogu C
    Am J Clin Oncol; 2008 Aug; 31(4):329-34. PubMed ID: 18845990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.
    Wolpin BM; Clark JW; Meyerhardt JA; Earle CC; Ryan DP; Enzinger PC; Zhu AX; Blaszkowsky L; Battu S; Fuchs CS
    Clin Colorectal Cancer; 2006 Sep; 6(3):208-13. PubMed ID: 17026790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemoradiotherapy of advanced resectable rectal cancer: results of a randomised trial comparing modulation of 5-fluorouracil with folinic acid or with interferon-α.
    Kornmann M; Staib L; Wiegel T; Kreuser ED; Kron M; Baumann W; Henne-Bruns D; Link KH
    Br J Cancer; 2010 Oct; 103(8):1163-72. PubMed ID: 20877353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck.
    Rodriguez CP; Adelstein DJ; Rybicki LA; Saxton JP; Lorenz RR; Wood BG; Scharpf J; Ives DI
    Head Neck; 2012 Nov; 34(11):1517-23. PubMed ID: 22180262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Combination of 5-Fluorouracil and folinic acid--is it still the standard therapy for advanced colorectal carcinoma?].
    Carnaghi C; Zucali P; Garassino I
    Tumori; 2000; 86(5 Suppl 2):S19-25. PubMed ID: 11195298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative radiation and concomitant bolus fluorouracil with or without additional chemotherapy with fluorouracil and high-dose leucovorin in patients with high-risk rectal cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group.
    Fountzilas G; Zisiadis A; Dafni U; Konstantaras C; Hatzitheoharis G; Liaros A; Athanassiou E; Dombros N; Dervenis C; Basdanis G; Gamvros O; Souparis A; Briasoulis E; Samantas E; Kappas A; Kosmidis P; Skarlos D; Pavlidis N
    Ann Oncol; 1999 Jun; 10(6):671-6. PubMed ID: 10442189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer.
    Cohen EE; Haraf DJ; Kunnavakkam R; Stenson KM; Blair EA; Brockstein B; Lester EP; Salama JK; Dekker A; Williams R; Witt ME; Grushko TA; Dignam JJ; Lingen MW; Olopade OI; Vokes EE
    J Clin Oncol; 2010 Jul; 28(20):3336-43. PubMed ID: 20498391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial.
    Lorvidhaya V; Chitapanarux I; Sangruchi S; Lertsanguansinchai P; Kongthanarat Y; Tangkaratt S; Visetsiri E
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1226-32. PubMed ID: 12654431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer.
    Kuo T; Cho CD; Halsey J; Wakelee HA; Advani RH; Ford JM; Fisher GA; Sikic BI
    J Clin Oncol; 2005 Aug; 23(24):5613-9. PubMed ID: 16110021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.